Wednesday, July 27, 2011
Tuesday, July 26, 2011
- http://www.clinicaltrials.gov/ has traditionally been the best database of clinical trials, yet it was not completely accurate on the eligibility window for one ALS trial. Since ALS patients are seldom diagnosed quickly (that's a whole other story), they often have very little time in their clinical-trial eligibility windows by the time they know they have ALS. It's a big deal if a trial will accept patients up to 36 months (rather than 24) from onset. Patient communication to the trial sponsor resulted in an important update to an important clinical trial's listing -- Neuraltus NP-001 -- http://www.clinicaltrials.gov/ct2/show/NCT01281631?term=neuraltus+amyotrophic&rank=1
- A new location was announced for the same clinical trial and within hours, our patient mapmaker had updated his work and communicated it to dozens of ALS websites.
- Several patients chided ALSadvocacy for not being more specific when referring to an important phase III trial in a prior posting. Here you go. -- Biogen Idec Dexpramipexole http://www.clinicaltrials.gov/ct2/show/NCT01281189?term=dexpramipexole&rank=3
- The facebook commentary regarding clinical trials has increased significantly. Patients are encouraging each other to "try out." Patients may or may not qualify, depending on how much damage the ALS has already done to them. The support and information being exchanged on facebook are impressive.
- Patients are hearing from their own trial coordinators of an uptick in inquiries based on patient referrals.
- Some trials provide unadvertised assistance with travel expenses. Patients are learning to ask.
- Finally, there are rumblings that some ALS organizations may finally be working together to make a single best information source of clinical trial possibilities. Based on past performance, that's a refreshing new goal to prove that it really is all about the patients. If a reliable, up-to-date, easy-to-use source of ALS clinical trial information emerges, then there may still be hope that all organizations might cooperate on having one excellent source of information. Patients have been begging for inter-organizational cooperation for years. This is a chance to help patients and leverage resources.
- There continue to be reports of large groups of patients at support groups and clinics who are not being informed of clinical trial options by their organizations and healthcare professionals.
- The online information regarding clinical trials has been updated on some ALS organization sites but not on others, and obsolete information is worse than no information! ALSA chapter sites are not accurate at this time. There is an old saying that everything is harder with ALS, and this is an ironic source that reinforces the adage. ALSadvocacy hopes that organizations will remove the red-herring information and simply supply a link to http://www.clinicaltrials.gov/ct2/results?term=amyotrophic&recr=Open It's all about the patients, right? It seems unconscionable that a patient might miss a trial opportunity based on wrong information on a trusted organization's site.
- Not all trial locations supply email addresses in addition to phone numbers for the contact people. A disease that steals the ability to speak would be served well with more appropriate communication options for patients to inquire about clinical trials.
- Clinics that are holding trials may occasionally be forgetting to tell patients about other clinical trial options that are available elsewhere. In the same vein, are not-for-profit trial sponsors forgetting to tell patients about trials sponsored by for-profit pharmaceutical companies?
Thursday, July 21, 2011
Right now there are some very interesting clinical trials being conducted for ALS. Over the years there have been hundreds of such "promising" trials, always with the quotation marks around "promising," and the disappointments and failures have been heartbreaking. This year it seems different. There are anecdotal reports of improvements in one trial. There is another that is a Phase III trial. Both are being led by some of the finest neurologists throughout the country. After all of the recent buzz and hope of finally removing the quotation marks from "promising," one fact remains -- we'll not know if these drugs will live up to the promise until the clinical trial seats are filled and the trials are completed.
One would think that patients with an untreatable, terminal disease would be knocking down the doors to get to these clinical trials. One would think. It seems that the process for getting information to ALS patients regarding clinical trials is horribly flawed. Many rely on their neurologists for information and guidance, yet often trials aren't introduced to patients and when they ask, the physician may not be familiar with the possibilities. Many rely on their trusted ALS organizations for information and guidance, yet we find a melange of outdated and incomplete information on their websites.
In the last few weeks, we have seen patients enrolled in trials taking matters into their own hands with some impressive results. Any patient who is enrolled in a clinical trial can be highly motivated to get the other seats in that trial filled so that it can move ahead. We see patients contacting others via social networking to encourage and inform regarding trials they are in. We see patients and caregivers asking trusted ALS organizations to speak up to patients regarding enrolling trials (and there have been some results). We see patients contributing to information online so that their peers can understand the relative advantages and disadvantages of trials. We even saw one patient who had traveled away from home for his monthly clinical trial infusion who dropped into a support group meeting in the clinical trial city. He found peers who were not aware of what was happening in their own back yard. One patient published a map online to show his peers all of the cities offering his trial. Facebook friends are posting information on walls wherever people with ALS and families might visit, and patients who do not qualify for trials are being a huge help to spread the word to others who might. Patients are posting their data at http://www.patientslikeme.com/ so that others may learn.
The system for spreading clinical trial information is broken. Some say there is no system. There is no excuse for a patient who qualifies for a clinical trial to be unaware of the possibility. Patients are leading the way right now. We hope that organizations and clinics and physicians will follow their lead and step it up a notch or ten!
Wednesday, July 20, 2011
Tuesday, July 19, 2011
Monday, July 18, 2011
Also, there is a beautifully written feature in USA Today by Liz Szabo --
Friday, July 15, 2011
Saturday, July 9, 2011
Diesel Pete made this college freshman think that national championships were the normal part of a college football experience. Many years later he showed this ALS advocate the meaning of courage when facing this beast of a disease.
Another of our best and brightest has been taken. When will we stop this madness?
Friday, July 8, 2011
Over the last several weeks there have been early reports of some positive results. It's way to early to know if early reports mean anything, but it is a most encouraging buzz among some of the trial participants.
If you have ALS or if you know someone with ALS, this Neuraltus NP001 trial might be worth some serious consideration. One must be within 36 months of disease onset to be eligible. If travel is required to get to a trial site, we understand that there is some assistance available.
We hope and we pray that this portends a viable treatment for ALS that can be delivered quickly. Around 500 Americans with ALS die every month.
Wednesday, July 6, 2011
I'm writing to you because I hope will will help spread the word about a remarkable man taking on a remarkable effort for the benefit of ALS research .....
In August, Doug McConnell, 53, of Barrington, Ill, will attempt to become the 48th person over the age of 50 to successfully cross the temperamental English Channel. He will be swimming more than 21 grueling miles in memory of his father who passed away from ALS (Lou Gehrig's disease). Doug is using this epic effort to educate the public about ALS and raise funds for medical research at Northwestern University ’s Feinberg School of Medicine in Chicago.
McConnell truly loves swimming and appreciates physical challenges. As a child, during a family vacation to England, he saw the Channel and thought to himself that one day he'd swim across the busy waterway. He and friend Don Macdonald committed to this endurance challenge and have been training for this event for approximately two years.
In late 2009, Doug developed a medical setback – a severely herniated disc between two cervical vertebrae, resulting in the loss of all use of his left arm. After physical therapy and other unsuccessful treatments, Doug underwent a cervical disc replacement procedure. The surgery was successful. Today, Doug has regained strength in his arm and the ability to move his neck to breathe while swimming, and he swims without pain. This was not enough to stop Doug's pursuit of his dream.
Medtronic, the manufacturer of the disc that was implanted into Doug's body, has pledged up to $50,000 in support of Doug's efforts. He is well on his way to raising a significant amount of money.
We hope you will post the press release on your blog. Please feel free to contact me with any questions or if you need additional information.
Les Turner ALS Foundation
Tuesday, July 5, 2011
...He talked about how CFF’s successes – more than 30 drugs in the development pipeline, four of them already FDA-approved – have been a result of holding its partners’ feet to the fire, and keeping patients at the table every step of the way to create the urgency Feigal talked about.
But it goes beyond just having a seat at the table. While patient presence is critical to humanizing research and speeding progress, patient voices can’t just be loud, they also have to be smart on the science and knowledgeable about the regulatory environment. The recently released paper Back to Basics: HIV/AIDS Advocacy as a Model for Catalyzing Change, co-authored by FasterCures and HCM Strategists, distills lessons learned from the HIV/AIDS movement that can be replicated to address today’s medical research advocacy challenges. HIV/AIDS activists were successful because they refused to accept that the system was unchangeable, and instead took the time to figure out what it should be and how it should work.
In case you didn't click on that Back to Basics: HIV/AIDS Advocacy as a Model for Catalyzing Change link, please do so. Perhaps there really is a roadmap after all.